Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and survival.
Authors
- Fang Zhao (ORCID: https://orcid.org/0000-0002-2746-9242)
- Anke Hinney (ORCID: https://orcid.org/0000-0001-5659-0706)
- Eva Hadaschik (ORCID: https://orcid.org/0000-0001-6305-5963)
- Patrick Terheyden (ORCID: https://orcid.org/0000-0002-5894-1677)
- Jochen Sven Utikal (ORCID: https://orcid.org/0000-0001-5316-0241)
- Edgar Dippel (ORCID: https://orcid.org/0000-0002-4433-2387)
- Rudolf Alexander Herbst (ORCID: https://orcid.org/0000-0002-4238-9486)
- Klaus Griewank (ORCID: https://orcid.org/0000-0003-3899-9449)
- Ralf Gutzmer (ORCID: https://orcid.org/0000-0001-7921-2820)
- Peter Möhr (ORCID: https://orcid.org/0000-0001-9639-6545)
- Jens Kleesiek (ORCID: https://orcid.org/0000-0001-8686-0682)
- Fabian Hörst (ORCID: https://orcid.org/0000-0002-8906-7644)
- Michael Weichenthal (ORCID: https://orcid.org/0000-0002-9060-4961)
- Claudia Pföhler (ORCID: https://orcid.org/0000-0003-0384-114X)
- Alexander Roesch (ORCID: https://orcid.org/0000-0002-0773-6067)
- Triinu Peters (ORCID: https://orcid.org/0000-0002-7341-2802)
- Wolfgang Galetzka
- Luisa Sophie Rajcsanyi (ORCID: https://orcid.org/0000-0003-1688-0316)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Friedegund Meier (ORCID: https://orcid.org/0000-0003-4340-9706)
- Birte Hellwig (ORCID: https://orcid.org/0000-0003-2806-7250)
- Annette Paschen (ORCID: https://orcid.org/0000-0003-1651-1262)
- Alpaslan Tasdogan (ORCID: https://orcid.org/0000-0003-2543-852X)
- Elisabeth Livingstone (ORCID: https://orcid.org/0000-0001-8279-9239)
- Antje Sucker (ORCID: https://orcid.org/0000-0002-2753-9626)
- Philipp Jansen (ORCID: https://orcid.org/0000-0003-3139-2118)
- Selma Ugurel (ORCID: https://orcid.org/0000-0002-9384-6704)
- Lisa Zimmer (ORCID: https://orcid.org/0000-0002-3680-3521)
- Jürgen Christian Becker (ORCID: https://orcid.org/0000-0001-9183-653X)
- Jörg Rahnenführer (ORCID: https://orcid.org/0000-0002-8947-440X)
- Alexander Kreuter (ORCID: https://orcid.org/0000-0003-2275-499X)
- Bernd Kowall (ORCID: https://orcid.org/0000-0003-4163-1696)
- Jens Ulrich
- Georg Lodde
- Jan-Malte Placke
Institutions
- German Cancer Research Center (DE)
- TU Dortmund University (DE)
- Heidelberg University (DE)
- University Hospital Bonn (DE)
- Dorothea Dix Hospital (US)
- University Hospital Heidelberg (DE)
- Institut für Medizinische Informatik, Biometrie und Epidemiologie (DE)
- Düsseldorf University Hospital (DE)
- Elisabeth-Krankenhaus Essen (DE)
- Universitäres Kinderwunschzentrum Lübeck (DE)
- University Hospital Schleswig-Holstein (DE)
- Essen University Hospital (DE)
- HELIOS St. Elisabeth Klinik Oberhausen (DE)
- Klinikum Ludwigshafen (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Helios Klinikum Erfurt (DE)
- West German Heart and Vascular Center Essen (DE)
- University Hospital Carl Gustav Carus (DE)
- Johannes Wesling Klinikum Minden (DE)
- Heinrich Heine University Düsseldorf (DE)
- Saarland University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.ejca.2024.114295
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Bristol-Myers Squibb
- Universität Duisburg-Essen